Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).
Annals of oncology : official journal of the European Society for Medical Oncology·2025